Tenax Therapeutics, Inc. (TENX) insider have most recently took part in a trading activity. On Dec 18, 2017 Blanck Ronald R, Director bought 12,950 shares having total worth of $5,828 at the price of $0.45 per share, following the transaction a total of 20,099 shares owned by Blanck Ronald R.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 sell activities .Furthermore, over the past 12 months , the stock was traded 1 times by insiders. In 1 of these trades, the insider was a seller .
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Tenax Therapeutics, Inc. (TENX) traded down 1.57% on Dec 19, 2017, hitting $0.44. 444,341 shares of the company’s stock traded hands. Tenax Therapeutics, Inc. has a 52 week low of $0.32 and a 52 week high of $2.73. The company’s market cap is $67 million.
Tenax Therapeutics, Inc. (TENX) last announced its earnings results on Mar 21, 2017. The company reported -0.15 earnings per share (EPS) for the quarter, same as the consensus estimate of -0.15.
|earnings per share||-0.15||-0.15||-0.17||-0.19||-0.36||-0.13||-0.11|
Oxygen Biotherapeutics, Inc. was originally formed as a New Jersey corporation in 1967 under the name Rudmer, David & Associates, Inc., and subsequently changed its name to Synthetic Blood International, Inc. The Company is engaged in the business of developing biotechnology products with a focus on oxygen delivery to specific target tissues. It is currently developing Oxycyte, a systemic perfluorocarbon, or PFC, product as oxygen carrier for use in situations of acute ischemia. In addition, it has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. The Company is actively pursuing agreements with multiple manufacturers to ensure that it is able to consistently obtain its raw materials and topical products timely, within its defined specifications, and at competitive prices. The manufacture and distribution of Oxycyte, as well as its other products, and the operation of its manufacturing facilities will require the approval of United States government authorities as well as those of foreign countries.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018